← Back to the full Peptide Guide overview
Important Disclaimer — Read Before Using This Page
This information is not intended for use by unlicensed individuals or by licensed professionals who lack adequate training and experience in assessing patients for peptide or hormone therapy. All clinical decisions and dosing must be made in consultation with a licensed, experienced physician and a licensed, experienced compounding pharmacist, and should be supported by published clinical studies.
The information presented here has been compiled using Artificial Intelligence, statements from videos and websites by apparent qualified professionals, and available published research. We strongly encourage exhaustive independent research before considering any therapy. Anyone starting a medication they have never taken before should take an extremely conservative approach.
Nothing on this page or in these videos should be taken as medical advice. These materials are provided only to help begin your research. All dosing and treatment decisions should be made between you and your medical providers after proper evaluation. We are not affiliated with any of the doctors whose videos appear on this page.
TB-500 Investigational Compounded
Also known as: Fequesetide; the actin-binding fragment (LKKTETQ) of thymosin beta-4
Category: Tissue Repair & Recovery — Synthetic Peptide Fragment
What it is. TB-500 is a short synthetic peptide corresponding to the active actin-binding region of thymosin beta-4. Where full-length TB4 is 43 amino acids, TB-500 is roughly seven—the key functional piece of a much larger molecule. It is easier and cheaper to synthesize, more stable in solution, and consequently far more common in the peptide market than full-length TB4. Related to TB4, derived from TB4, but a distinct compound; see our Thymosin Beta-4 page for the parent protein.
How it works, and why physicians pair it with BPC-157. The proposed mechanism follows TB4's: actin regulation driving cell migration, angiogenesis, and tissue remodeling, with anti-inflammatory effects layered on top. Because it distributes systemically through the bloodstream rather than acting only where injected, it is often chosen for patients with multiple injury sites or chronic soft-tissue problems, where injecting each individual site is impractical. That systemic profile is also why it is so commonly stacked with BPC-157—the pairing you see in our recovery blends—with BPC-157 framed as the localized repair signal and TB-500 as the systemic one.
Where the evidence actually is, and the regulatory picture. The systemic regenerative literature for TB-500 is largely rodent and cell-based; high-quality human outcome data does not exist. A 2026 review in The American Journal of Sports Medicine concluded that TB-500 shows early preclinical promise but that key questions on dosing, safety, and clinical outcomes remain unanswered. Regulatory status has been in motion: the FDA removed TB-500 from its Section 503A Category 2 list in April 2026, and in July 2026 an FDA advisory committee recommended adding it to the Section 503A Bulks List for wound healing—an advisory vote, not drug approval, with no final agency decision as of this writing. Availability through compounding pharmacies can shift quarter to quarter; your prescriber should verify current status before every prescription. TB-500 is prohibited by WADA at all times. Reported effects are generally mild—injection-site reactions, fatigue, or lightheadedness after a dose.
Recommended Videos
Quinn Stillson, MD — TB-500 & TB-4: Everything You Need to Know — Benefits, Risks, Dosing & vs BPC-157
Dr. Adam Sewell, MD — Unlocking TB-500: Dosage, Benefits & Clinical Success for Regenerative Medicine
Thomas DeLauer — The Best Muscle Building & Fat Loss Peptide | TB-500 (Thymosin Beta 4) Benefits & Risks
Video Sources & Independence
The videos linked on this page are provided solely for educational purposes. None of the physicians or channels featured are sponsored by, affiliated with, or compensated by NJ Weight Loss & Preventive Care Clinics, its physicians, or any individuals associated with our practice. We have selected these videos because they offer thoughtful, evidence-based discussion of mechanisms and clinical considerations. Viewers should evaluate all sources independently.
← Back to the full Peptide Guide overview · Peptide Dosing Reference →